A podcast for the rising stars of the start-up community
Marks & Clerk presents a podcast series created specifically for the start-up community, helping founders understand the importance of embedding intellectual property (IP) into their business strategy from day one.
Featuring insights from experienced founders, investors and commercialisation experts, this series addresses the realities of IP strategy, funding, market validation and the challenges of scaling technology. Each episode offers clear, practical guidance - from navigating university licensing to overcoming the "three…
BOSTON, MA and LONDON, UK – March 11, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Syntis Bio, Inc. and is pleased to announce the placement of David Rosenbaum, Ph.D. as Chief Development Officer (CDO). Syntis Bio is a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine to treat obesity and rare metabolic diseases. As CDO, Dr. Rosenbaum will oversee the company’s clinical and technical development…
Sandwich, UK - 9 March 2026: SignaCor Therapeutics has been named the winner of Discovery Park's startup growth programme for innovations in cardiovascular health, securing £250k in funding from venture capital firm Zinc. This investment forms part of a £1M seed round expected to close in April.
Northern Ireland-based SignaCor is developing medicines for hypertrophic cardiomyopathy, where thickening of the heart muscle makes it harder for blood to be pumped around the body. This genetically inherited cardiac disorder affects around 1 in 500 people in the UK.
Led by CEO Darach Neeson and…
For over 30 years, UCLB has built a sustained engine of commercial success, turning exceptional UCL research into ventures and licensing deals across every discipline.
The UCL 2026 Impact Report demonstrates how this work is having real-world impact, from changing patients’ lives with new personalised treatments for leukaemia, to making businesses more efficient with the use of AI tools, to empowering communities to have their voices heard with data and maps.
We hope you are inspired by these examples, because truly exceptional ideas deserve a chance to change the world, with the expert…
PHILADELPHIA, PA – February 26, 2026 – Quotient Sciences, a leading integrated CRDMO (Contract Research, Development and Manufacturing Organization), is pleased to announce an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.
This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs. Sohonos (Palovarotene…
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US $3 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the…
Europa Biosite Acquires Stratech Scientific, Expanding Their Product Offering and Strengthening UK Customer Reach
Europa Biosite, a leading pan-European life science distribution group, today announced the acquisition of Stratech Scientific Limited by its UK subsidiary, Cambridge Bioscience. Stratech Scientific is a well-respected and long-established UK life science distributor, known for its high-quality research reagents and strong supplier partnerships.
This acquisition significantly expands Europa Biosite’s UK product offering and broadens its reach across academic and…
LONDON, UK and BRUSSELS, Belgium – March 5, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Evondos Group and is pleased to announce the placement of Tom Ellison as Chief Financial Officer (CFO). Evondos Group is the leading provider of automated medicine dispensing services in northern Europe. Their solutions ensure safe and timely medication for home care clients, improving patient safety, treatment outcomes and quality of life. By supporting healthcare professionals,…
Provides structured US market access for EvoLiver FDA-designated liver cancer surveillance test across health systems, payors and clinical stakeholders
Cambridge, UK, and Boston MA, USA, 04 March 2026: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve chronic disease outcomes for at-risk patients, today announced it has been selected to join the Association of British HealthTech Industries (ABHI) US Accelerator. Building on the Company’s US presence, the programme will support the introduction of EvoLiver™, its FDA-designated liver cancer…
Drug development consultancy Boyds has appointed Kate Owen as Medical Director in its Clinical and Medical Affairs team.
With more than 25 years’ experience as a pharmaceutical physician specialising in early development oncology, haemato-oncology, clinical pharmacology and ATMPs, Kate began her career training as an anaesthetist before working for a CRO. She then spent 16 years at AstraZeneca where she worked as Medicine and Science Director. In 2016, Kate became an independent consultant working with companies around the globe across small molecules, biologics, medical devices and cell…